hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06382727 id: ER008 briefTitle: CONTINUation of Enteral Nutrition Prior to Extubation Compared to Standard Care acronym: CONTINUE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-04 date: 2024-04-24 date: 2024-04-24 name: Emma Ridley class: OTHER briefSummary: Critically ill patients admitted to the Intensive Care Unit (ICU) often need to be connected to a breathing machine (ventilator) and are unable to eat. During this time, liquid nutrition is delivered via a feeding tube to the stomach or bowel (termed enteral nutrition (EN)) to ensure nutrition needs are provided until such time that the patient can eat normally.
This study is a pilot randomised controlled trial of fasting patients for at least 4 hours prior to removal of the breathing tube compared with not pausing EN. The investigators hypothesise that this will reduce the number of hours of fasting in the 24 hours prior to extubation. conditions: Critical Illness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: CONTINUE is a multi-centre, open-label, prospective parallel, pilot randomised controlled trial being conducted in Australia. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 60 type: ESTIMATED name: EN will be continued up to extubation (EN will not be withheld prior to extubation) measure: Fasting time (hours) measure: Reintubation rate measure: Days alive and free of mechanical ventilation measure: Commencement of antibiotics measure: Ratio of oxygen saturation (SpO2)/ fraction of inspired oxygen (FiO2) measure: ICU length of stay measure: In-hospital mortality measure: Nutrition delivery measure: Recruitment rate measure: Protocol compliance sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Gold Coast University Hospital city: Southport state: Queensland zip: 4215 country: Australia name: James Mccullogh, Dr role: CONTACT lat: -27.96724 lon: 153.39796 facility: St Vincent's Hospital Melbourne city: Fitzroy state: Victoria zip: 3065 country: Australia name: Alastair Brown, Dr role: CONTACT lat: -37.79839 lon: 144.97833 facility: The Alfred Hospital city: Melbourne state: Victoria zip: 3004 country: Australia name: Emma Ridley, A/Prof role: CONTACT name: Sean Keem, Dr role: CONTACT lat: -37.814 lon: 144.96332 hasResults: False
nctId: NCT06382701 id: Kayseri briefTitle: Effect of Aromatherapy on Pain, Anxiety and Satisfaction in Cannulation overallStatus: ACTIVE_NOT_RECRUITING date: 2021-09-06 date: 2024-06-30 date: 2024-06-30 date: 2024-04-24 date: 2024-04-24 name: TC Erciyes University class: OTHER briefSummary: The most active members of the healthcare professionals responsible for hemodialysis units are nurses, and they have a key role in pain, anxiety and satisfaction management as they are responsible for cannulation. Therefore, complementary and integrated practices need to be implemented based on evidence to strengthen the independent role of nurses in managing pain and anxiety. conditions: Hemodialysis Patients studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study was designed as a randomized controlled and double-blind study to evaluate the effect of clove oil applied to arterio-venous fistula on pain and anxiety caused by cannulation and to determine the effect of the application on satisfaction. primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE maskingDescription: Pre-cannulation spray application to the intervention and placebo groups will be provided by an interviewer trained by the researchers. Cannulations will be performed by nurses in the institution where the study is conducted. Data will be collected by the responsible nurses in the institutions.
The research will be completed in twelve sessions over four weeks. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: aromatherapy name: placebo measure: Visual Analog Scale (VAS) measure: State and Trait Anxiety Inventory (STAI) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erciyes University city: Melikgazi state: Kayseri zip: 38260 country: Turkey hasResults: False
nctId: NCT06382688 id: 23-08-0010 briefTitle: IV Administration of ChromaDex's Niagen® as Compared to NAD+ overallStatus: ACTIVE_NOT_RECRUITING date: 2023-11-13 date: 2024-03-08 date: 2024-08-31 date: 2024-04-24 date: 2024-04-24 name: Franklin Health Research class: OTHER briefSummary: This is a 2-part study evaluating the effects of IV administration of NR on healthy adult populations. Study 1 involved all four arms with 37 people. The second study only included the active NR and NAD+ arms to further evaluate tolerability and comfort of the IV. conditions: Healthy Aging studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 53 type: ACTUAL name: NAD+ (nicotinamide adenine dinucleotide) IV name: Niagen® (nicotinamide riboside) IV name: Niagen® (nicotinamide riboside) oral name: Placebo measure: Blood Pressure measure: Heart rate measure: Total NAD measured through dried blood spot testing measure: Glucose measure: Insulin Levels measure: total NAD measured through blood and plasma measure: Tolerable Infusion Rate measure: Complete Blood Count measure: Comprehensive Metabolic Panel measure: Sleep Scale measure: Energy Scale measure: Subjective Experience sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nutraceuticals Research Institute city: Franklin state: Tennessee zip: 37067 country: United States lat: 35.92506 lon: -86.86889 hasResults: False
nctId: NCT06382675 id: TA-PF-01-DE id: CIV-23-11-044643 type: OTHER domain: Unique identification number EUDAMED briefTitle: Clinical Performance of the New Plasma Filter PX2 in TPE Treatments acronym: plasmaFlux overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2025-03 date: 2024-04-24 date: 2024-04-24 name: Fresenius Medical Care Deutschland GmbH class: INDUSTRY name: KLIFO GmbH briefSummary: The plasma filter is applied for a single use in extracorporeal blood purification therapy. The intended purpose is the separation of plasma from blood by filtration, in conditions, which are associated with increased concentration of plasma components where a rapid depletion slows down or stops a pathogenic process.
The investigation involves the collection of treatment data of the new Plasma Filter PX2 in combination with the multiFiltrate and multiFiltratePRO in therapeutic plasma exchange (TPE) treatments. The multiFiltrate and multiFiltratePRO are devices for extracorporeal blood purification treatments. No further control treatments will be investigated in this one arm design. The design is considered to be appropriate to reflect daily clinical practice and to contribute to empirical evidence of performance of the new Plasma Filter PX2. No specific treatment schedule is defined by the study protocol. The TPE treatment is performed with the plasma filter PX2 (investigational device) according to clinical practice established in each of the participating centers and are prescribed at the discretion of the treating physician. The participation in the study will have no influence on the treatment plan. The documentation of the treatment includes the therapy up to the tenth (10th) treatment. conditions: Autoimmune Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Interventional, single arm, multi-centric, open-label primaryPurpose: TREATMENT masking: NONE count: 46 type: ESTIMATED name: Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2 measure: Analysis of TPE treatments with the Plama Filter PX2 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Klinikum Aschaffenburg-Alzenau city: Aschaffenburg state: Bavaria zip: 63739 country: Germany name: Stefan Büttner, Dr. med. role: CONTACT email: Stefan.buettner@klinikum-ab-alz.de lat: 49.97704 lon: 9.15214 facility: Städtisches Klinikum Braunschweig city: Braunschweig state: Niedersachsen zip: 38126 country: Germany name: Gabriele Eden, Dr. med. role: CONTACT email: g.eden@skbs.de lat: 52.26594 lon: 10.52673 hasResults: False
nctId: NCT06382662 id: PMDAC-01 briefTitle: Effect of Metaxalone 640 mg (M640) on Truck Driving Ability and Cognition Compared to Other Skeletal Muscle Relaxants overallStatus: RECRUITING date: 2024-04-15 date: 2025-04-15 date: 2025-04-15 date: 2024-04-24 date: 2024-04-26 name: Primus Pharmaceuticals class: INDUSTRY name: Sun Valley Arthritis Center briefSummary: Every participant will receive active study drug and (tone) 1 comparator, in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal. Vital signs and discussion of medications, illness or injury are considered safety assessments and will be discussed at every visit. There will be (four) 4 visits. conditions: Cognitive Impairment studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: This is a prospective, randomized, single-blind, pilot study to assess degree of drowsiness, cognition, and driving risk following a single dose of oral metaxalone 640 mg (M640) versus metaxalone 800 mg in healthy subjects. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: metaxalone m640 name: Tizanidine measure: Change from baseline, Standard Deviation of Lateral Position measure: Change from baseline of participants' reasoning ability to recognize differences in six (6) computer generated shapes for 30 minutes measure: Change from baseline of participants' subjective report of drowsiness on a 10-point scale measure: Percentage of participants unable to maintain Tandem Stand Position for more than 10 seconds (position 3 of the 4-Stage Balance Test) measure: The number of product related adverse events experienced by participants from Visit 1 through Visit 4 sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Valley Arthritis Center status: RECRUITING city: Peoria state: Arizona zip: 85381 country: United States name: Study Investigator role: CONTACT phone: 623-566-3550 email: jtuber@svacltd.com name: Study Coordinator role: CONTACT phone: 623-566-3550 lat: 33.5806 lon: -112.23738 hasResults: False
nctId: NCT06382649 id: 202403051 briefTitle: Rivastigmine for Antimuscarinic Delirium acronym: RIVA-AM overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-07 date: 2026-07 date: 2024-04-24 date: 2024-04-25 name: Washington University School of Medicine class: OTHER name: American Academy of Clinical Toxicology briefSummary: Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production.
Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo. conditions: Anticholinergic Toxicity studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 42 type: ESTIMATED name: Rivastigmine name: Placebo measure: Time to control of agitation and delirium measure: Duration of agitation and delirium measure: Total amount of sedatives administered measure: Use of sedative infusions measure: Use of physical restraints measure: Disposition measure: Time to medical clearance measure: Oversedation measure: Intubation measure: Seizure measure: Gastrointestinal upset measure: Bradycardia sex: ALL minimumAge: 10 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Washington University School of Medicine city: Saint Louis state: Missouri zip: 63110 country: United States name: Kevin Baumgartner role: CONTACT phone: 314-273-1109 email: baumgartner.k@wustl.edu lat: 38.62727 lon: -90.19789 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-04-10 uploadDate: 2024-04-19T15:42 filename: ICF_000.pdf size: 1060713 hasResults: False
nctId: NCT06382636 id: 23-101 briefTitle: Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes acronym: OPUS overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2027-02-28 date: 2027-02-28 date: 2024-04-24 date: 2024-04-24 name: The Cleveland Clinic class: OTHER briefSummary: The goal of this study is to ensure that pregnant patients have the resources and support needed to access Prenatal Screening \& Diagnostic Testing (PS\&D) in an informed and evidence-based fashion by developing an innovative digital tool to support patients' decision-making and contributing fundamental knowledge to advance science in a way that promotes patients' access to new prenatal applications of genomic science and technology. Our central hypothesis is that, by focusing on patient engagement as a key driver to improve patient outcomes, the use of an evidence-based artificial-intelligence (AI) powered patient engagement tool will increase patients' ability to seek information and structure a decision-making process that, in turn, increases informed decisions about PS\&D and decreases decisional conflict associated with those decisions.
Using data from NEST (Ensuring Patients Informed Access to NIPT \[non-invasive prenatal testing\]), the investigators designed the next iteration of NEST, a point-of care shared decision-making tool powered by artificial intelligence (AI) to provide a personalized and dynamic decision support tool: Obstetric Prenatal Genetic Testing Engagement Solution (OPUS). OPUS is an AI-enabled healthcare chatbot (a computer program capable of processing and simulating human conversation) that provides patients with personalized information and decision-making support at different stages of the PS\&D pathway. It functions using a series of questions contained in the NEST with a branching logic sequence of questions and answers based on the responses to and from the patient, using a conversational and adaptable interaction. It also contains nested tiers of information, ranging from introductory to detailed information about patient engagement, health literacy, the different PS\&D options, and resources to learn about insurance coverage for PS\&D. OPUS was designed to be accessed by patients with different technological resources and preferences, using a cell phone, a mobile device, or a computer. conditions: Prenatal Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 600 type: ESTIMATED name: Standard Care name: Obstetric Prenatal Genetic Testing Engagement Solution (OPUS) AI Chatbot measure: Patient activation sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Neighborhood Family Practice city: Cleveland state: Ohio zip: 44102 country: United States name: Heidi Gullett, MD role: CONTACT phone: 216-368-0776 email: hlg31@case.edu lat: 41.4995 lon: -81.69541 facility: MetroHealth Medical Center city: Cleveland state: Ohio zip: 44109 country: United States name: Angela Ranzini, MD role: CONTACT phone: 216-778-3513 email: aranzini@metrohealth.org lat: 41.4995 lon: -81.69541 facility: Cleveland Clinic city: Cleveland state: Ohio zip: 44195 country: United States name: Ruth Farrell, MD, MA role: CONTACT phone: 216-445-7085 email: farrelr@ccf.org name: Christina Collart, MEd role: CONTACT phone: 216-470-9796 email: collarc@ccf.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06382623 id: 43 briefTitle: Efficacies of Different Managements in Patients With Trigger Finger overallStatus: COMPLETED date: 2022-10-01 date: 2023-06-30 date: 2023-06-30 date: 2024-04-24 date: 2024-04-24 name: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital class: OTHER briefSummary: The aim of the study is to compare the effectiveness of peritendinous steroid injection under ultrasound guidance and percutaneous A1 pulley release procedures in terms of disease stage, pain, and severity of locking in patients with trigger finger. conditions: Trigger Finger studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ACTUAL name: The percutaneous A1 pulley release name: The peritendinous Betamethasone group measure: Stage of the disease measure: Pain intensity measure: severity of triggering sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Gaziler Physical Medicine and Rehabilitation Education and Research Hospital city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06382610 id: 2024-002 briefTitle: Pharmacokinetics of Melatonin Administered in Oral, Lotion, and Bubble Bath Formulations overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2024-12-15 date: 2024-12-15 date: 2024-04-24 date: 2024-04-24 name: University of Redlands class: OTHER briefSummary: Melatonin is a hormone that promotes sleep that is available without a prescription in the United States. In addition to oral supplements, melatonin can be purchased in the form of lotions and bubble baths with unknown dosage and no frequency or age recommendations. In this study, researchers will examine how quickly melatonin in lotion and bubble bath is absorbed compared to oral tablets, as well as how long the melatonin lasts in the body. conditions: Sleep studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Repeated measures crossover trial primaryPurpose: BASIC_SCIENCE masking: NONE count: 10 type: ESTIMATED name: Melatonin measure: Salivary melatonin level measure: Side effects sex: ALL minimumAge: 18 Years maximumAge: 22 Years stdAges: ADULT facility: University of Redlands city: Redlands state: California zip: 92373 country: United States lat: 34.05557 lon: -117.18254 hasResults: False
nctId: NCT06382597 id: AWFiS/2024_2_P-GM briefTitle: Four Weeks of Nordic Hamstring Exercises Impact the Strength and Balance of the Hamstring Muscle Group overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-07-10 date: 2024-07-10 date: 2024-04-24 date: 2024-04-24 name: Gdansk University of Physical Education and Sport class: OTHER briefSummary: The aim of the study is to assess the impact of 4 weeks of eccentric Nordic Hamstring Exercise training on changes in the hamstring muscle group, as well as to analyze parameters such as maximum muscle strength of the knee flexors, RFD (rate of force development) and static balance, dynamics for the dominant leg. conditions: Hamstring Injury studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 2 type: ESTIMATED name: Nordic hamstring exercise measure: Biodex Balance System measure: Biodex System sex: ALL minimumAge: 19 Years maximumAge: 26 Years stdAges: ADULT hasResults: False
nctId: NCT06382584 id: IRB_23.09.01 briefTitle: Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur acronym: ANTI_XA overallStatus: COMPLETED date: 2022-01-01 date: 2023-06-01 date: 2023-06-01 date: 2024-04-24 date: 2024-04-24 name: Centre Hospitalier Universitaire de Nīmes class: OTHER briefSummary: In 2023, oral anticoagulant treatments (anti Xa: apixaban , rivaroxaban, etc.) are tending to replace anti vitamin K treatments in many medical indications. Their prescription is increasing rapidly in the elderly.
In this context, the Nimes University Hospital receives a large number of elderly patients who have suffered a fracture of the end of the femur requiring surgery and who are taking anti Xa drugs.To avoid massive intra- and post-operative haemorrhage, surgical management is postponed because of the need to suspend the treatment, allowing a return to near-normal biological haemostasis within a few days. No consensus has been reached on the withdrawal period required to authorise surgery, as the elimination kinetics of the drug are altered in this context (elderly patients, dehydration, hypovolaemia, impaired renal function). A plasma assay (threshold of \<30 to 60 ng/mL) has been proposed without any real justification. This waiting period exposes the elderly to excess mortality. Reversing these treatments by adding coagulation factors would be an attractive alternative, as it would allow surgery to be performed earlier, but this would expose patients to an increased thrombotic risk.
Before considering a prospective randomised study (early vs delayed surgery on AOD), we wish to retrospectively analyse data on patients admitted to the Nimes University Hospital on anti Xa and operated on for fracture of the upper end of the femur between 1 January 2022 and 1 June 2023 conditions: Direct Oral Anticoagulants (DOACs) conditions: Femoral Fractures conditions: Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 610 type: ACTUAL name: Femoral fracture surgery measure: Hospital Mortality measure: Duration of the surgery measure: Transfusion measure: Postoperative comorbidities measure: Hospital stay measure: Anti Xa assay sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: CHU de NIMES city: Nimes zip: 30029 country: France lat: 43.83333 lon: 4.35 hasResults: False
nctId: NCT06382571 id: 026/66 briefTitle: Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients overallStatus: COMPLETED date: 2016-01-01 date: 2020-12-31 date: 2021-12-31 date: 2024-04-24 date: 2024-04-24 name: Chulalongkorn University class: OTHER briefSummary: Objective: To analyze factors associated with Thai heart failure with reduced ejection fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor blockers (ARBs).
Methods: The retrospective cohort study was designed to collect data on Thai heart failure with reduced ejection fraction patients at Out-patient Clinic, Trat Hospital and Phrapokklao Hospital from January 2016 to December 2020. Thirteen factors were analyzed to determine their association with the sub-target group. conditions: Heart Failure With Reduced Ejection Fraction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 396 type: ACTUAL name: Renin-Angiotensin System Inhibitor measure: factors associated with sub - target dose of ACEIs,ARBs,ARNI sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False